113. 筋ジストロフィー Muscular dystrophy Clinical trials / Disease details


臨床試験数 : 646 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

  
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05429372
(ClinicalTrials.gov)
August 8, 20228/10/2021Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular DystrophyA PHASE 2, MULTICENTER, SINGLE-ARM STUDY TO EVALUATE THE SAFETY AND DYSTROPHIN EXPRESSION AFTER FORDADISTROGENE MOVAPARVOVEC (PF-06939926) ADMINISTRATION IN MALE PARTICIPANTS WITH EARLY STAGE DUCHENNE MUSCULAR DYSTROPHYMuscular Dystrophy, DuchenneGenetic: PF-06939926PfizerNULLRecruiting2 Years3 YearsMale10Phase 2United States;Australia
2EUCTR2019-002921-31-BE
(EUCTR)
18/06/202107/09/2020Phase 3 study to evaluate the safety and efficacy of PF-06939926 for the treatment of Duchenne muscular dystrophy.A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY DUCHENNE MUSCULAR DYSTROPHY (DMD)
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: PF-06939926
Product Code: PF-06939926
INN or Proposed INN: PF-06939926
Other descriptive name: Adeno-associated viral vector serotype 9 containing the human mini-dystrophin gene
Pfizer Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes
99Phase 3United States;Taiwan;Spain;Israel;Russian Federation;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Germany;China;Japan;Korea, Republic of
3EUCTR2019-002921-31-FR
(EUCTR)
15/03/202107/09/2020Phase 3 study to evaluate the safety and efficacy of PF-06939926 for the treatment of Duchenne muscular dystrophy.A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY DUCHENNE MUSCULAR DYSTROPHY (DMD)
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: PF-06939926
Product Code: PF-06939926
INN or Proposed INN: PF-06939926
Other descriptive name: Adeno-associated viral vector serotype 9 containing the human mini-dystrophin gene
Pfizer Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes
99Phase 3United States;Taiwan;Spain;Israel;Russian Federation;United Kingdom;Italy;Switzerland;France;Canada;Belgium;Germany;China;Japan;Korea, Republic of
4EUCTR2019-002921-31-IT
(EUCTR)
04/12/202006/11/2020Phase 3 study to evaluate the safety and efficacy of PF-06939926 for the treatment of Duchenne muscular dystrophy.A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY - - DUCHENNE MUSCULAR DYSTROPHY (DMD)
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: PF-06939926
Product Code: [PF-06939926]
INN or Proposed INN: PF-06939926
PFIZER INCNULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes
99Phase 3United States;Taiwan;Spain;Israel;Russian Federation;United Kingdom;Italy;Switzerland;France;Canada;Belgium;Germany;China;Japan;Korea, Republic of
5NCT04281485
(ClinicalTrials.gov)
November 5, 202011/2/2020Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular DystrophyA PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF 06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHYDuchenne Muscular DystrophyGenetic: PF-06939926;Other: PlaceboPfizerNULLRecruiting4 Years7 YearsMale99Phase 3United States;Australia;Belgium;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Switzerland;Taiwan;United Kingdom
6EUCTR2019-002921-31-GB
(EUCTR)
29/09/202002/07/2020Phase 3 study to evaluate the safety and efficacy of PF-06939926 for the treatment of Duchenne muscular dystrophy.A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY DUCHENNE MUSCULAR DYSTROPHY (DMD)
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: PF-06939926
Product Code: PF-06939926
INN or Proposed INN: PF-06939926
Other descriptive name: Adeno-associated viral vector serotype 9 containing the human mini-dystrophin gene
Pfizer Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes
99Phase 3United States;Taiwan;Spain;Israel;Russian Federation;United Kingdom;Italy;Switzerland;France;Canada;Belgium;Germany;China;Japan;Korea, Republic of
7NCT03362502
(ClinicalTrials.gov)
January 23, 201829/11/2017A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular DystrophyA PHASE 1B MULTICENTER, OPEN-LABEL, SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PF-06939926 IN AMBULATORY AND NON-AMBULATORY SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHYDuchenne Muscular DystrophyGenetic: PF-06939926PfizerNULLActive, not recruiting4 YearsN/AMale23Phase 1United States
8EUCTR2019-002921-31-DE
(EUCTR)
28/07/2020Phase 3 study to evaluate the safety and efficacy of PF-06939926 for the treatment of Duchenne muscular dystrophy.A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY DUCHENNE MUSCULAR DYSTROPHY (DMD)
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: PF-06939926
Product Code: PF-06939926
INN or Proposed INN: PF-06939926
Other descriptive name: Adeno-associated viral vector serotype 9 containing the human mini-dystrophin gene
Pfizer Inc.NULLNAFemale: no
Male: yes
99Phase 3United States;Taiwan;Spain;Israel;Russian Federation;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Germany;China;Japan;Korea, Republic of